At a glance
ClinicalIndex Comparison RecordN/ACompleted· 260 enrolled
Drug / intervention
CELSTAT +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective, Randomized, Controlled Study to Evaluate the Effectiveness and Safety of CELSTAT as an Adjunct to Hemostasis for Tissue Bleeding in Cardiothoracic, General, and Vascular Surgery.
In Brief
A clinical study evaluating CELSTAT and Surgicel Original for Bleeding Active. Completed, enrolled 260 participants across 25 sites in 4 countries.
Detailed Summary
The study is to evaluate the effectiveness and safety of CELSTAT vs active control.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBleeding Active
CountriesCzechia, Germany, Poland, United States
Collaborators--
Timeline
N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedDec 2015
Enrollment StartFeb 2016
Primary CompletionJul 2017
Study CompletionOct 2017
TodayJul 2026
First PostedDec 28, 2015
Enrollment StartFeb 24, 2016
Primary CompletionJul 21, 2017
Study CompletionOct 18, 2017
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 10.5 years ago
Interventions
CELSTATdevice
Surgicel Originaldevice